Photodynamic methods of treatment of nonmuscular-invasive bladder cancer

Abstract

The review article is devoted to the application of photodynamic therapy for non-muscle invasive bladder cancer. The data on the mechanism and pathogenetic bases of the application of this method of treatment, the method of its implementation, the advantages and disadvantages of the photosensitizers and the results of clinical studies are presented. It has been shown that intraoperative photodynamic therapy significantly reduces the rate of recurrence of bladder cancer after transurethral resection, including in patients with carcinoma in situ and multifocal growth of urothelial tumors.

Keywords

bladder cancer / photosensitizer / photodynamic therapy / theranostics

References

[1] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. DOI: 10.1016/j.ejca.2012.12.027

[2] Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 // Eur J Cancer. 2013. Vol. 49, No. 6. P. 1374–403. DOI: 10.1016/j.ejca.2012.12.027

[3] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. DOI: 10.3322/caac.21387

[4] Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017 // CA Cancer J Clin. 2017. Vol. 67, No. 1. P. 7–30. DOI: 10.3322/caac.21387

[5] Tan WS, Rodney S, Lamb B, et al. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31. DOI: 10.1016/j.ctrv.2016.05.002

[6] Tan W.S., Rodney S., Lamb B., et al. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia // Cancer Treat Rev. 2016. Vol. 47. P. 22–31. DOI: 10.1016/j.ctrv.2016.05.002

[7] Babjuk M., Burger M., Compérat E., et al; European Association of Urology. Non-muscle-invasive Bladder Cancer (TaT1 and CIS). EAU Guideline. [Internet]. 2021. Available from: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/#7. Cited: 2022 Jan 12.

[8] Babjuk M., Burger M., Compérat E., et al; European Association of Urology. Non-muscle-invasive Bladder Cancer (TaT1 and CIS). EAU Guideline [Интернет]. 2021. Режим доступа: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. Дата обращения: 20.12.2021.

[9] Rak mochevogo puzyrja. Klinicheskie rekomendacii MZ RF [Internet]. 2020. https://cr.minzdrav.gov.ru/schema/11_2. Cited: 2022 Jan 12.

[10] Рак мочевого пузыря. Клинические рекомендации МЗ РФ [Интернет]. 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/11_2. Дата обращения: 20.12.2021.

[11] Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol. 2005;174(6):2134–2137. DOI: 10.1097/01.ju.0000181799.81119.fc

[12] Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy // J Urol. 2005. Vol. 174, No. 6. P. 2134–2137. DOI: 10.1097/01.ju.0000181799.81119.fc

[13] Chamie K, Litwin MS, Bassett JC, et al. Urologic Diseases in America Project. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219–3227. DOI: 10.1002/cncr.28147

[14] Chamie K., Litwin M.S., Bassett J.C., et al. Urologic Diseases in America Project. Recurrence of high-risk bladder cancer: a population-based analysis // Cancer. 2013. Vol. 119, No. 17. P. 3219–3227. DOI: 10.1002/cncr.28147

[15] Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68(3):549–553. DOI: 10.1016/j.urology.2006.03.062

[16] Avritscher E.B., Cooksley C.D., Grossman H.B., et al. Clinical model of lifetime cost of treating bladder cancer and associated complications // Urology. 2006. Vol. 68, No. 3. P. 549–553. DOI: 10.1016/j.urology.2006.03.062

[17] Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300. DOI: 10.1007/s00345-009-0395-z

[18] Sievert K.D., Amend B., Nagele U., et al. Economic aspects of bladder cancer: what are the benefits and costs? // World J Urol. 2009. Vol. 27, No. 3. P. 295–300. DOI: 10.1007/s00345-009-0395-z

[19] Jesionek A, von Tappeiner H. On the treat-ment of skin carcinomas with fluorescent substances. Dtsch Arch Klin Med. 1905;82: 223–226. (In German)

[20] Jesionek A., von Tappeiner H. Zur Behandlung der Hautcarcinome mit fluoreszierenden Stoffen // Dtsch Arch Klin Med. 1905. Vol. 82. P. 223–226. (In German)

[21] Filonenko EV, Serova LG. Photodynamic therapy in clinical practice. Biomedical Photonics. 2016;5(2):26–37. (In Russ.)

[22] Филоненко Е.В., Серова Л.Г. Фотодинамическая терапия в клинической практике // Biomedical Photonics. 2016. Vol. 5, No. 2. P. 26–37.

[23] Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol. 1991;53(4):549–553. DOI: 10.1111/j.1751-1097.1991.tb03669.x

[24] Moan J., Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen // Photochem Photobiol. 1991. Vol. 53, No. 4. P. 549–553. DOI: 10.1111/j.1751-1097.1991.tb03669.x

[25] Akopov AL, Kazakov NV, Rusanov AA, Karlson A. The mechanisms of photodynamic action for treating of cancer patients. Photodynamic therapy and photodyagnosis. 2015;4(2):9–16. (In Russ.) DOI: 10.24931/2413-9432-2015-4-2-9-16

[26] Акопов А.Л., Казаков Н.В., Русанов А.А., Карлсон А. Механизмы фотодинамического воздействия при лечении онкологических больных // Фотодинамическая терапия и фотодиагностика. 2015. Vol. 4, No. 2. P. 9–16. DOI: 10.24931/2413-9432-2015-4-2-9-16

[27] Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers (Basel). 2011;3(2):2516–2539. DOI: 10.3390/cancers3022516

[28] Mroz P., Yaroslavsky A., Kharkwal G.B., Hamblin M.R. Cell death pathways in photodynamic therapy of cancer // Cancers (Basel). 2011. Vol. 3, No. 2. P. 2516–2539. DOI: 10.3390/cancers3022516

[29] Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150(5): S146–S156.

[30] Oleinick N.L., Evans H.H. The photobiology of photodynamic therapy: cellular targets and mechanisms // Radiat Res. 1998. Vol. 150, No. 5. P. S146–S156.

[31] Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2005;2(1):1–23. DOI: 10.1016/S1572-1000(05)00030-X

[32] Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death // Photodiagnosis Photodyn Ther. 2005. Vol. 2, No. 1. P. 1–23. DOI: 10.1016/S1572-1000(05)00030-X

[33] Nowis D, Makowski M, Stokłosa T, et al. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol. 2005;52(2):339–352.

[34] Nowis D., Makowski M., Stokłosa T., et al. Direct tumor damage mechanisms of photodynamic therapy // Acta Biochim Pol. 2005. Vol. 52, No. 2. P. 339–352.

[35] Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002;1(1):1–21. DOI: 10.1039/b108586g

[36] Oleinick N.L., Morris R.L., Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how // Photochem Photobiol Sci. 2002. Vol. 1, No. 1. P. 1–21. DOI: 10.1039/b108586g

[37] Zharkov VV, Pristupa DV, Mal’kevich VT. Photodynamic therapy in oncology. Photodynamic therapy for lung cancer. Onkologicheskij zhurnal. 2015;9(1):84–93. (In Russ.)

[38] Жарков В.В., Приступа Д.В., Малькевич В.Т. Фотодинамическая терапия в онкологии. Фотодинамическая терапия рака легкого // Онкологический журнал. 2015. Vol. 9, No. 1. P. 84–93.

[39] Alsaab HO, Alghamdi MS, Alotaibi AS, et al. Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine. Cancers (Basel). 2020;12(10):2793. DOI: 10.3390/cancers12102793

[40] Alsaab H.O., Alghamdi M.S., Alotaibi A.S., et al. Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine // Cancers (Basel). 2020. Vol. 12, No. 10. P. 2793. DOI: 10.3390/cancers12102793

[41] Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol. 1976;115(2):150–151. DOI: 10.1016/s0022-5347(17)59108-9

[42] Kelly J.F., Snell M.E. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder // J Urol. 1976. Vol. 115, No. 2. P. 150–151. DOI: 10.1016/s0022-5347(17)59108-9

[43] Hisazumi H, Misaki T, Miyoshi N. Photoradiation therapy of bladder tumors. J Urol. 1983;130(4):685–687. DOI: 10.1016/s0022-5347(17)51403-2

[44] Hisazumi H., Misaki T., Miyoshi N. Photoradiation therapy of bladder tumors // J Urol. 1983. Vol. 130, No. 4. P. 685–687. DOI: 10.1016/s0022-5347(17)51403-2

[45] Uchibayashi T, Koshida K, Kunimi K, Hisazumi H. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder. Br J Cancer. 1995;71(3):625–628. DOI: 10.1038/bjc.1995.122

[46] Uchibayashi T., Koshida K., Kunimi K., Hisazumi H. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder // Br J Cancer. 1995. Vol. 71, No. 3. P. 625–628. DOI: 10.1038/bjc.1995.122

[47] Yamamoto S, Fukuhara H, Karashima T, Inoue K. Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety. Photodiagnosis Photodyn Ther. 2020;32:101999. DOI: 10.1016/j.pdpdt.2020.101999

[48] Yamamoto S., Fukuhara H., Karashima T., Inoue K. Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: Diagnostic accuracy and safety // Photodiagnosis Photodyn Ther. 2020. Vol. 32. P. 101999. DOI: 10.1016/j.pdpdt.2020.101999

[49] Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer. 1987;56(5):589–595. DOI: 10.1038/bjc.1987.246

[50] Malik Z., Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins // Br J Cancer. 1987. Vol. 56, No. 5. P. 589–595. DOI: 10.1038/bjc.1987.246

[51] Kasymov BG, Shanazarov NA, Muratov TM, et al. Photodynamic diagnostics of non-muscle-invasive bladder cancer. Urology reports (St.-Petersburg). 2021;11(2):163–174 (In Russ.) DOI: 10.17816/uroved58165

[52] Касымов Б.Г., Шаназаров Н.А., Муратов Т.М., и др. Фотодинамическая диагностика немышечно-инвазивного рака мочевого пузыря // Урологические ведомости. 2021. Т. 11, № 2. С. 163–174. DOI: 10.17816/uroved58165

[53] Inoue K, Fukuhara H, Kurabayashi A, et al. Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma. Cancer Sci. 2013;104(6): 765–772. DOI: 10.1111/cas.12147

[54] Inoue K., Fukuhara H., Kurabayashi A., et al. Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma // Cancer Sci. 2013. Vol. 104, No. 6. P. 765–772. DOI: 10.1111/cas.12147

[55] Shackley DC, Briggs C, Gilhooley A, et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int. 2002;89(7):665–670. DOI: 10.1046/j.1464-410x.2002.02743.x

[56] Shackley D.C., Briggs C., Gilhooley A., et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic // BJU Int. 2002. Vol. 89, No. 7. P. 665–670. DOI: 10.1046/j.1464-410x.2002.02743.x

[57] Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology. 2003;61(2):338–341. DOI: 10.1016/s0090-4295(02)02123-4

[58] Berger A.P., Steiner H., Stenzl A., et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study // Urology. 2003. Vol. 61, No. 2. P. 338–341. DOI: 10.1016/s0090-4295(02)02123-4

[59] Waidelich R, Beyer W, Knüchel R, et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology. 2003;61(2):332–337. DOI: 10.1016/s0090-4295(02)02164-7

[60] Waidelich R., Beyer W., Knüchel R., et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source // Urology. 2003. Vol. 61, No. 2. P. 332–337. DOI: 10.1016/s0090-4295(02)02164-7

[61] Filonenko EV, Kaprin AD, Alekseev BY, et al. 5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial). Photodiagnosis Photodyn Ther. 2016;16:106–109. DOI: 10.1016/j.pdpdt.2016.09.009

[62] Filonenko E.V., Kaprin A.D., Alekseev B.Y., et al. 5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial) // Photodiagnosis Photodyn Ther. 2016. Vol. 16. P. 106–109. DOI: 10.1016/j.pdpdt.2016.09.009

[63] Fotinos N, Campo MA, Popowycz F, et al. 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol. 2006;82(4):994–1015. DOI: 10.1562/2006-02-03-IR-794

[64] Fotinos N., Campo M.A., Popowycz F., et al. 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives // Photochem Photobiol. 2006. Vol. 82, No. 4. P. 994–1015. DOI: 10.1562/2006-02-03-IR-794

[65] Slesarevskaya MN, Sokolov AV, Kuzmin IV. Photosensitizer in diagnostic and treatment of oncourological diseses. Urologicheskie vedomosti. 2013;3(4):10–13. (In Russ.) DOI: 10.17816/uroved3410-13

[66] Слесаревская М.Н., Соколов А.В., Кузьмин И.В. Фотосенсибилизаторы в диагностике и лечении онкоурологических заболеваний // Урологические ведомости. 2013. Т. 3, № 4. С. 10–13. DOI: 10.17816/uroved3410-13

[67] Slesarevskaya MN, Sokolov AV. Photodynamic therapy (PDT): The main principles and mechanism of action. Urologicheskie vedomosti. 2012;2(3):24–28. (In Russ.) DOI: 10.17816/uroved2324-28

[68] Слесаревская М.Н., Соколов А.В. Фотодинамическая терапия: основные принципы и механизмы действия // Урологические ведомости. 2012. Т. 2, № 3. С. 24–28. DOI: 10.17816/uroved2324-28

[69] Yagudajev DM, Geinitz AV, Martov AG, Sorokatiy AE. The first results of PDT used for urinary bladder cancer. Laser Medicine. 2004; 8(3):242 (In Russ.)

[70] Ягудаев Д.М., Гейниц А.В., Мартов А.Г., Сорокатый А.Е. Первые результаты применения фотодинамической терапии при раке мочевого пузыря // Лазерная медицина. 2004. № 3. С. 242.

[71] Kagan OF, Kheifets VKh, Plekhanov AYu. Experience with a novel photodynamic therapy technique for superficial bladder carcinoma. Oncourology. 2011;(3):80–85. (In Russ.)

[72] Каган О.Ф., Хейфец В.Х., Плеханов А.Ю. Опыт нового метода фотодинамической терапии поверхностного рака мочевого пузыря // Онкоурология. 2011. № 3. С. 80–85.

[73] Slesarevskaya MN, Sokolov AV. Experience of application ofphotodynamic therapy in the combined treatment of superficial bladder cancer. Urologicheskie vedomosti. 2012;2(4):12–15. (In Russ.) DOI: 10.17816/uroved2412-15

[74] Слесаревская М.Н., Соколов А.В. Опыт применения фотодинамической терапии в комбинированном лечении поверхностного рака мочевого пузыря // Урологические ведомости. 2012. Т. 2, № 4. С. 12–15. DOI: 10.17816/uroved2412-15

[75] Lee JY, Diaz RR, Cho KS, et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy. J Urol. 2013;190(4):1192–1199. DOI: 10.1016/j.juro.2013.04.077

[76] Lee J.Y., Diaz R.R., Cho K.S., et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy // J Urol. 2013. Vol. 190, No. 4. P. 1192–1199. DOI: 10.1016/j.juro.2013.04.077

[77] Salnikova SV, Ivanchenko LP, Lopyrev AI, et al. Place of photodynamic therapy in the complex treatment of muscular non-invasive urothelial cancer. Kremlin Medicine Journal. 2020;(1):16–21. (In Russ.) DOI: 10.26269/t8xc-wd12

[78] Сальникова С.В., Иванченко Л.П., Лопырев А.И., и др. Место фотодинамики в комплексном лечении мышечно-неинвазивного уротелиального рака // Кремлевская медицина. 2020. № 1. С. 16–21. DOI: 10.26269/t8xc-wd12

[79] Shanazarov NA, Sholokh PI, Akhmetzakirov RR, et al. Opyt primeneniya fotodinamicheskoy terapii pri lechenii poverkhnostnykh form raka mochevogo puzyrya. Оңтүстік қазақстан meditsina akademiyasy khabarshy. 2019;(3):68. (In Russ.)

[80] Шаназаров Н.А., Шолох П.И., Ахметзакиров Р.Р, и др. Опыт применения фотодинамической терапии при лечении поверхностных форм рака мочевого пузыря // Оңтүстік Қазақстан медицина академиясының хабаршысы. 2019. № 3. С. 68.

[81] Benberin VV, SHanazarov NA, SHoloh PI, et al. Opyt primeneniya fotodinamicheskoj terapii pri lechenii poverhnostnyh form raka mochevogo puzyrya. Proceedings of the VII Congress of Oncologists of Kazakhstan with international participation (2019 Oct 17–18, Nur-Sultan). The Oncology and Radiology of Kazakhstan. 2019;(Suppl.):68 (In Russ.)

[82] Бенберин В.В., Шаназаров Н.А., Шолох П.И., и др. Опыт применения фотодинамической терапии при лечении поверхностных форм рака мочевого пузыря / Сборник тезисов VII съезда онкологов и радиологов Казахстана с международным участием (17–18 октября 2019 г., г. Нур-Султан) // Онкология и радиология Казахстана. 2019. № S. C. 68.

[83] Babaev AB, Loran OB. Photodynamic therapy with the domestic fluorescent video system of non-muscle invasive bladder cancer. Russian Medical Journal. 2019;27(2):61–66. (In Russ.)

[84] Бабаев А.Б., Лоран О.Б. Фотодинамическая тераностика отечественной флуоресцентной видеосистемой немышечно-инвазивного рака мочевого пузыря // РМЖ. 2019. Т. 27, № 2. С. 61–64.

RIGHTS & PERMISSIONS

Kasymov B.G., Shanazarov N.A., Muratov T.M., Daniyarova G.D., Zhumakayev A.M., Kyzlasov P.S., Kazhera A.A., Slesarevskaya M.N., Kuzmin I.V., Al-Shukri S.K.